Assessment of intravenous immunotherapy with purified F(ab')2 fragments (Viperfav(TM));Evaluation de I'immunotherapie anti-viperine par fragments F(ab')2 purifies (Viperfav(TM)) par voie veineuse

Presse Medicale

Volumn 28, Issue 35, 1999, Pages 1929-1934

  Harry, P ^a   De Haro, L ^b   Asfar, P ^a   David, J M ^b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; SNAKE VENOM ANTISERUM; UNCLASSIFIED DRUG; VIPERFAV; IMMUNOGLOBULIN F(AB) FRAGMENT; VIPER VENOM;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY; SNAKEBITE; ANIMAL; CHILD; COMPARATIVE STUDY; HORSE; IMMUNOLOGY; INTOXICATION; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANIMALS; CHILD; FEMALE; HORSES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; MALE; MIDDLE AGED; POISONING; RETROSPECTIVE STUDIES; VIPER VENOMS;

EID: 0033552333     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Sorkine M. Les morsures de serpents en France: aspects cliniques, biologiques et thérapeutiques. In: Envenimations Perspectives en Réanimation eds Amette Blackwell, Paris 1996 ; 83-93.
2. Audebert F, Sorkine M, Bon C. Envenoming by viper bites in France: clinical gradation and biological quantification by Elisa. Toxicon 1992 ; 30:599-609.
3. Audebert F, Sorkine M, Robbe-Vincent A, Bon C, Viper bites in France: clinical and biological evaluation; kinetics of envenomations. Hum Experim Toxicol 1994 ; 13:683-8.
4. Bon C, Audebert F, Choumet V, Rivière G, Sorkine M. Pharmacocinétique du venin et mécanisme de l'immunothérapie. In: Envenimations Perspectives en réanimation eds Amette Blackwell, Paris 1996, 95-102.
5. Pepin S, Lutsch C, Grandgeorge M, Sherrmann JM. Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. Pharmaceutical Research 1995 ; 12:1470-3.
6. Karlson-Stiber C, Persson H. Antivenom treatment in Vipera berus envenoming - report of 30 cases. J Intern Med 1994 ; 235:57-61.
7. Nelson B K. Snake envenomation incidence, clinical presentation and managment. Medical Toxicol 1989 ; 4:17-31.
8. De Haro L, Lang J, Bedry R et al. Envenimations par vipères européennes. Etude multicentrique de tolérance du Viperfav™, nouvel antivenin par voie intraveineuse. Ann Fr Anesth Réanim 1998 ; 17:681-7.
9. Lachaux A, Floret D, Hartemann E, Berthier J-C, Armand JP. Les formes mortelles d'envenimation par les vipères en France a propos de trois observations pédiatriques. JEUR 1990 ; 4:249-53.
10. Karlson-Stiber C, Persson H, Heath A, Smith D, Al-Abdulla I H, Sjöström L. First clinical experiences with spedfic sheep fab fragments in snake bite. Report of a multicenter study of Vipera berus envenoming. J Intern Med 1997; 241:53-8.
11. Stahel ER. The use of antivenin in the treatment of viper bites in Switzerland and its influence on the duration of hospitalisation, (abstract) Toxicon 1985 ; 23:626.
12. Thomas L, Tyburn B, Lang J et al. Tolérance et efficacité d'un fragment F(ab')2 antivenimeux (équin) spécifique administré par voie intraveineuse dans le traitement des morsures de serpent (Bothrops lanceolatus) en Martinique. Réan Urg 1998 ; 7:381-7.
13. Bentur Y, Zveibel F, Adler M, Raikhlin B. Delayed administration of Vipera xanthina palaestinae antivenin. Clin Toxicol 1997 ; 35:257-61.